Risperidone: Difference between revisions
ClaireLewis (talk | contribs) |
(Text replacement - "*Pancreatitis" to "*Pancreatitis") |
||
| Line 24: | Line 24: | ||
*Prolonged QT, sudden cardiac death, syncope | *Prolonged QT, sudden cardiac death, syncope | ||
*DKA | *DKA | ||
*Pancreatitis | *[[Pancreatitis]] | ||
*Cytopenias, TTP | *Cytopenias, TTP | ||
*Stroke, seizure, tardive dyskinesia, priapism | *Stroke, seizure, tardive dyskinesia, priapism | ||
Revision as of 21:06, 25 September 2016
Administration
- Type: Atypical antipsychotic
- Dosage Forms:
- Routes of Administration: Oral, IM
- Common Trade Names: Risperdal
Adult Dosing
- 2-6mg PO daily
- 25-50mg IM
Pediatric Dosing
- Pediatric procedural sedation: 0.01mg/kg/dose IM (typically 0.25-4mg/dose)
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal: severe impairment, 0.5mg twice daily, titrate slowly
- Hepatic: lower initial dose
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Prolonged QT, sudden cardiac death, syncope
- DKA
- Pancreatitis
- Cytopenias, TTP
- Stroke, seizure, tardive dyskinesia, priapism
- Neuroleptic malignant syndrome
Common
- Akasthisia, dystonia, parkinsonism
- Sedation/fatigue, dizziness, blurred vision, anxiety
- Rash
- Hyperprolactinemia, weight gain, increased appetite
- Constipation, diarrea, nausea/vomiting
- Cough, URI
Pharmacology
- Half-life:
- Metabolism: Hepatic, CYP2D6
- Excretion:
Mechanism of Action
- Unknown
- 5HT-2 inhibitor, weaker D2 inhibitor